ARTICLE | Distillery Therapeutics


March 22, 2018 4:58 PM UTC

Patient sample, cell culture and mouse studies suggest inhibiting RIPK1 or MCU could help treat colorectal cancer. In patient samples, tumor levels of RIPK1 and MCU were higher than in adjacent normal tissues. In a human colorectal cancer cell line, siRNA targeting RIPK1 decreased proliferation compared with scrambled siRNA. In a xenograft mouse model of colorectal cancer, shRNA targeting RIPK1 or MCU decreased tumor growth compared with non-specific shRNA. Next steps could include identifying and testing MCU inhibitors in models of colorectal cancer.

GlaxoSmithKline plc has the RIPK1 inhibitor 2982772 (GSK2982772) in Phase II testing to treat rheumatoid arthritis, ulcerative colitis and psoriasis...